Gossamer Bio Inc (GOSS)

Sep 24, 2026

Gossamer Bio submitted a New Drug Application (NDA) for its pulmonary arterial hypertension treatment, seralutinib, despite its pivotal Phase 3 PROSERA trial missing its primary statistical endpoint. The FDA now has 60 days to decide whether to file the application for review, a decision anticipated later in 2026. The company's shares closed at US$10.99, and it reported US$57.0 million in cash, which is expected to fund operations into Q1 2027.

Sep 17, 2026

Gossamer Bio (NASDAQ: GOSS) is holding a special meeting on October 27, 2026, to ask shareholders to approve issuing common stock exceeding 20% of current outstanding shares. This approval is crucial for converting warrants and preferred stock into common shares, which could significantly impact the company's future financing and strategic flexibility. If approved, it would lead to dilution for existing shareholders not participating in the private placement, while rejection would limit financing options.

Sep 16, 2026

Gossamer Bio, a clinical-stage biopharmaceutical company, announced the appointment of Greg Ciongoli to its Board of Directors, effective September 16, 2026. Mr. Ciongoli, founder of Adiumentum Capital Management and former Partner at the Baupost Group, will also join the Audit Committee. His extensive investment background is expected to be a significant asset as the company advances seralutinib for pulmonary hypertension towards potential FDA approval.